Top

Published in:

01-06-2017 | Original Article

MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children

Authors: Ma. C. Sánchez-Gómez, K. A. García-Mejía, M. Pérez-Díaz Conti, G. Díaz-Rosas, I. Palma-Lara, R. Sánchez-Urbina, M. Klünder-Klünder, J. A. Botello-Flores, N. A. Balderrábano- Saucedo, A. Contreras-Ramos

Published in: Pediatric Cardiology | Issue 5/2017

Abstract

Complex congenital heart disease (CHD) affects cardiac blood flow, generating a pressure overload in the compromised ventricles and provoking hypertrophy that over time will induce myocardial dysfunction and cause a potential risk of imminent death. Therefore, the early diagnosis of complex CHD is paramount during the first year of life, with surgical treatment of patients favoring survival. In the present study, we analyzed cardiac tissue and plasma of children with cardiac hypertrophy (CH) secondary to CHD for the expression of 11 miRNAs specific to CH in adults. The results were compared with the miRNA expression patterns in tissue and blood of healthy children. In this way, we determined that miRNAs 1, 18b, 21, 23b, 133a, 195, and 208b constitute the expression profile of the cardiac tissue of children with CHD. Meanwhile, miRNAs 21, 23a, 23b, and 24 can be considered specific biomarkers for the diagnosis of CH in infants with CHD. These results suggest that CH secondary to CHD in children differs in its mechanism from that described for adult hypertrophy, offering a new perspective to study the development of this pathology and to determine the potential of hypertrophic miRNAs to be biomarkers for early CH.

Allen HD, Driscoll DJ, Shaddy RE, Feltes TF (2013) Moss & adams’ heart disease in infants, children, and adolescents: including the fetus and young adult. Wolters Kluwer Health, Philadelphia

Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E, Pilote L (2007) Congenital heart disease in the general population: changing prevalence and age distribution. Circulation 115(2):163–172. doi: 10.1161/CIRCULATIONAHA.106.627224 CrossRefPubMed

Hoffman JI, Christianson R (1978) Congenital heart disease in a cohort of 19,502 births with long-term follow-up. Am J Cardiol 42(4):641–647CrossRefPubMed

Yang Q, Chen H, Correa A, Devine O, Mathews TJ, Honein MA (2006) Racial differences in infant mortality attributable to birth defects in the United States, 1989–2002. Birth Defects Res Part A 76(10):706–713. doi:10.1002/bdra.20308 CrossRef

Hofmann U, Ertl G, Frantz S (2011) Toll-like receptors as potential therapeutic targets in cardiac dysfunction. Expert Opin Ther Targets 15(6):753–765. doi:10.1517/14728222.2011.566560 CrossRefPubMed

de la Cruz MV, Markwald RR, Krug EL, Rumenoff L, Sanchez Gomez C, Sadowinski S, Galicia TD, Gomez F, Salazar Garcia M, Villavicencio Guzman L, Reyes Angeles L, Moreno-Rodriguez RA (2001) Living morphogenesis of the ventricles and congenital pathology of their component parts. Cardiol Young 11(6):588–600CrossRefPubMed

Escudero EM, Pinilla OA (2007) Paradigms and paradoxes of left ventricular hypertrophy: from the research laboratory to the clinical consultation. Arch Cardiol Mex 77(3):237–248PubMed

Lane RE, Cowie MR, Chow AW (2005) Prediction and prevention of sudden cardiac death in heart failure. Heart 91(5):674–680. doi:10.1136/hrt.2003.025254 CrossRefPubMedPubMedCentral

Sander TL, Klinkner DB, Tomita-Mitchell A, Mitchell ME (2006) Molecular and cellular basis of congenital heart disease. Pediatr Clin N Am 53(5):989–1009, doi:10.1016/j.pcl.2006.08.010 CrossRef

10.

D’Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, Rubino M, Carena MC, Spazzafumo L, De Simone M, Micheli B, Biglioli P, Achilli F, Martelli F, Maggiolini S, Marenzi G, Pompilio G, Capogrossi MC (2010) Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31(22):2765–2773. doi:10.1093/eurheartj/ehq167ehq167 CrossRefPubMedPubMedCentral

11.

Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J (2007) MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 116(3):258–267. doi: 10.1161/CIRCULATIONAHA.107.687947 CrossRefPubMed

12.

Oliveira-Carvalho V, Carvalho VO, Silva MM, Guimaraes GV, Bocchi EA (2012) MicroRNAs: a new paradigm in the treatment and diagnosis of heart failure? Arq Bras Cardiol 98(4):362–369 pii]CrossRefPubMed

13.

Divakaran V, Mann DL (2008) The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 103(10):1072–1083. doi:10.1161/CIRCRESAHA.108.183087103/10/1072 CrossRefPubMedPubMedCentral

14.

Matkovich SJ, Wang W, Tu Y, Eschenbacher WH, Dorn LE, Condorelli G, Diwan A, Nerbonne JM, Dorn GW 2nd (2010) MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts. Circ Res 106(1):166–175. doi:10.1161/CIRCRESAHA.109.202176 CrossRefPubMed

15.

Suarez Y, Fernandez-Hernando C, Pober JS, Sessa WC (2007) Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100(8):1164–1173.doi: 10.1161/01.RES.0000265065.26744.17 CrossRefPubMed

16.

Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M (2007) MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100(3):416–424.doi: 10.1161/01.RES.0000257913.42552.23 CrossRefPubMed

17.

Suckau L, Fechner H, Chemaly E, Krohn S, Hadri L, Kockskamper J, Westermann D, Bisping E, Ly H, Wang X, Kawase Y, Chen J, Liang L, Sipo I, Vetter R, Weger S, Kurreck J, Erdmann V, Tschope C, Pieske B, Lebeche D, Schultheiss HP, Hajjar RJ, Poller WC (2009) Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation 119(9):1241–1252. doi:10.1161/CIRCULATIONAHA.108.783852 CrossRefPubMedPubMedCentral

18.

van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN (2006) A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA 103(48):18255–18260. doi: 10.1073/pnas.0608791103 CrossRefPubMedPubMedCentral

19.

Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, Pu WT (2009) MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 29(8):2193–2204. doi:10.1128/MCB.01222-08 CrossRefPubMedPubMedCentral

20.

Ai J, Zhang R, Gao X, Niu HF, Wang N, Xu Y, Li Y, Ma N, Sun LH, Pan ZW, Li WM, Yang BF (2012) Overexpression of microRNA-1 impairs cardiac contractile function by damaging sarcomere assembly. Cardiovasc Res 95(3):385–393. doi:10.1093/cvr/cvs196 CrossRefPubMed

21.

Da Costa A, Gate-Martinet A, Rouffiange P, Cerisier A, Nadrouss A, Bisch L, Romeyer-Bouchard C, Isaaz K (2012) Anatomical factors involved in difficult cardiac resynchronization therapy procedure: a non-invasive study using dual-source 64-multi-slice computed tomography. Europace 14(6):833–840. doi:10.1093/europace/eur350 CrossRefPubMed

22.

Gladka MM, da Costa Martins PA, De Windt LJ (2012) Small changes can make a big difference—microRNA regulation of cardiac hypertrophy. J Mol Cell Cardiol 52(1):74–82. doi:10.1016/j.yjmcc.2011.09.015 CrossRefPubMed

23.

Li Q, Song XW, Zou J, Wang GK, Kremneva E, Li XQ, Zhu N, Sun T, Lappalainen P, Yuan WJ, Qin YW, Jing Q (2010) Attenuation of microRNA-1 derepresses the cytoskeleton regulatory protein twinfilin-1 to provoke cardiac hypertrophy. J Cell Sci 123(14):2444–2452. doi:10.1242/jcs.067165

24.

Karakikes I, Chaanine AH, Kang S, Mukete BN, Jeong D, Zhang S, Hajjar RJ, Lebeche D (2013) Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload-induced cardiac hypertrophy and attenuates pathological remodeling. J Am Heart Assoc 2(2):e000078. doi:10.1161/JAHA.113.000078 CrossRefPubMedPubMedCentral

25.

Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, Olson EN (2008) microRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 22 (23):3242–3254. doi:10.1101/gad.1738708 CrossRefPubMedPubMedCentral

26.

Elia L, Quintavalle M, Zhang J, Contu R, Cossu L, Latronico MV, Peterson KL, Indolfi C, Catalucci D, Chen J, Courtneidge SA, Condorelli G (2009) The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ 16(12):1590–1598. doi:10.1038/cdd.2009.153 CrossRefPubMedPubMedCentral

27.

Courts C, Grabmuller M, Madea B (2013) Dysregulation of heart and brain specific micro-RNA in sudden infant death syndrome. Forensic Sci Int 228(1–3):70–74. doi:10.1016/j.forsciint.2013.02.032 CrossRefPubMed

28.

Chen Z, Li C, Xu Y, Li Y, Yang H, Rao L (2014) Circulating level of miR-378 predicts left ventricular hypertrophy in patients with aortic stenosis. PloS ONE 9(8):e105702. doi:10.1371/journal.pone.0105702 CrossRefPubMedPubMedCentral

29.

Li J, Cao Y, Ma XJ, Wang HJ, Zhang J, Luo X, Chen W, Wu Y, Meng Y, Zhang J, Yuan Y, Ma D, Huang GY (2013) Roles of miR-1-1 and miR-181c in ventricular septal defects. Int J Cardiol 168(2):1441–1446. doi:10.1016/j.ijcard.2012.12.048 CrossRefPubMed

30.

Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, Zhang Y, Xu C, Bai Y, Wang H, Chen G, Wang Z (2007) The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13(4):486–491. doi:10.1038/nm1569 CrossRefPubMed

31.

Reddy S, Zhao M, Hu DQ, Fajardo G, Hu S, Ghosh Z, Rajagopalan V, Wu JC, Bernstein D (2012) Dynamic microRNA expression during the transition from right ventricular hypertrophy to failure. Physiol Genom 44(10):562–575. doi:10.1152/physiolgenomics.00163.2011 CrossRef

32.

Gupta MP (2007) Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol 43(4):388–403. doi:10.1016/j.yjmcc.2007.07.045 CrossRefPubMedPubMedCentral

33.

Nelson TJ, Balza R Jr, Xiao Q, Misra RP (2005) SRF-dependent gene expression in isolated cardiomyocytes: regulation of genes involved in cardiac hypertrophy. J Mol Cell Cardiol 39(3):479–489. doi:10.1016/j.yjmcc.2005.05.004 CrossRefPubMed

34.

Hu X, Li T, Zhang C, Liu Y, Xu M, Wang W, Jia Z, Ma K, Zhang Y, Zhou C (2011) GATA4 regulates ANF expression synergistically with Sp1 in a cardiac hypertrophy model. J Cell Mol Med 15(9):1865–1877. doi:10.1111/j.1582-4934.2010.01182.x CrossRefPubMedPubMedCentral

35.

Molkentin JD, Olson EN (1997) GATA4: a novel transcriptional regulator of cardiac hypertrophy? Circulation 96(11):3833–3835PubMed

36.

Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD (2004) Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ Res 94(1):110–118. doi:10.1161/01.RES.0000109415.17511.18 CrossRefPubMed

37.

Houser SR, Molkentin JD (2008) Does contractile Ca2 + control calcineurin-NFAT signaling and pathological hypertrophy in cardiac myocytes? Sci Signal 1(25):e31. doi:10.1126/scisignal.125pe31 CrossRef

38.

Jiang DS, Luo YX, Zhang R, Zhang XD, Chen HZ, Zhang Y, Chen K, Zhang SM, Fan GC, Liu PP, Liu DP, Li H (2014) Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 63(1):119–127. doi:10.1161/HYPERTENSIONAHA.113.02083 CrossRefPubMed

39.

Oka T, Maillet M, Watt AJ, Schwartz RJ, Aronow BJ, Duncan SA, Molkentin JD (2006) Cardiac-specific deletion of Gata4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ Res 98(6):837–845. doi:10.1161/01.RES.0000215985.18538.c4 CrossRefPubMed

40.

Molkentin JD, Kalvakolanu DV, Markham BE (1994) Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene. Mol Cell Biol 14(7):4947–4957CrossRefPubMedPubMedCentral

41.

Ip HS, Wilson DB, Heikinheimo M, Leiden JM, Parmacek MS (1995) The GATA-4 transcription factor transactivates the cardiac-specific troponin C promoter-enhancer in non-muscle cells. Adv Exp Med Biol 382:117–124CrossRefPubMed

42.

Murphy AM, Thompson WR, Peng LF, Jones L 2nd (1997) Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4. Biochem J 322(Pt 2):393–401CrossRefPubMedPubMedCentral

43.

Charvet C, Auberger P, Tartare-Deckert S, Bernard A, Deckert M (2002) Vav1 couples T cell receptor to serum response factor-dependent transcription via a MEK-dependent pathway. J Biol Chem 277(18):15376–15384. doi:10.1074/jbc.M111627200 CrossRefPubMed

44.

Yang SH, Galanis A, Sharrocks AD (1999) Targeting of p38 mitogen-activated protein kinases to MEF2 transcription factors. Mol Cell Biol 19(6):4028–4038CrossRefPubMedPubMedCentral

45.

Zhao M, New L, Kravchenko VV, Kato Y, Gram H, di Padova F, Olson EN, Ulevitch RJ, Han J (1999) Regulation of the MEF2 family of transcription factors by p38. Mol Cell Biol 19(1):21–30CrossRefPubMedPubMedCentral

46.

Zhang Y, Zhang L, Chu W, Wang B, Zhang J, Zhao M, Li X, Li B, Lu Y, Yang B, Shan H (2010) Tanshinone IIA inhibits miR-1 expression through p38 MAPK signal pathway in post-infarction rat cardiomyocytes. Cell Physiol Biochem 26(6):991–998. doi:10.1159/000324012 CrossRefPubMed

47.

McKinsey TA, Zhang CL, Olson EN (2002) MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci 27(1):40–47CrossRefPubMed

48.

Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Hoydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G (2007) MicroRNA-133 controls cardiac hypertrophy. Nat Med 13(5):613–618. doi:10.1038/nm1582 CrossRefPubMed

49.

Schier JJ, Adelstein RS (1982) Structural and enzymatic comparison of human cardiac muscle myosins isolated from infants, adults, and patients with hypertrophic cardiomyopathy. J Clin Invest 69(4):816–825CrossRefPubMedPubMedCentral

50.

Hua Y, Zhang Y, Ren J (2012) IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and microRNA-133a. J Cell Mol Med 16(1):83–95. doi:10.1111/j.1582-4934.2011.01307.x CrossRefPubMed

51.

Zhang HS, Wu QY, Xu M, Zhou YX, Shui CX (2012) Mitogen-activated protein kinase signal pathways play an important role in right ventricular hypertrophy of tetralogy of Fallot. Chin Med J (Engl) 125(13):2243–2249

52.

Nomura S (2017) Extracellular vesicles and blood diseases. Int J Hematol. doi:10.1007/s12185-017-2180-x

53.

Ibrahim A, Marban E (2016) Exosomes: fundamental biology and roles in cardiovascular physiology. Annu Rev Physiol 78:67–83. doi:10.1146/annurev-physiol-021115-104929 CrossRefPubMed

54.

Fang L, Ellims AH, Moore XL, White DA, Taylor AJ, Chin-Dusting J, Dart AM (2015) Circulating microRNAs as biomarkers for diffuse myocardial fibrosis in patients with hypertrophic cardiomyopathy. J Transl Med 13:314. doi:10.1186/s12967-015-0672-0 CrossRefPubMedPubMedCentral

55.

Zile MR, Gottdiener JS, Hetzel SJ, McMurray JJ, Komajda M, McKelvie R, Baicu CF, Massie BM, Carson PE, Investigators IP (2011) Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction. Circulation 124(23):2491–2501. doi:10.1161/CIRCULATIONAHA.110.011031 CrossRefPubMed

56.

Schulte C, Zeller T (2015) microRNA-based diagnostics and therapy in cardiovascular disease-summing up the facts. Cardiovasc Diagn Ther 5(1):17–36. doi:10.3978/j.issn.2223-3652.2014.12.03 PubMedPubMedCentral

57.

Wang GK, Zhu JQ, Zhang JT, Li Q, Li Y, He J, Qin YW, Jing Q (2010) Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans. Eur Heart J 31(6):659–666. doi:10.1093/eurheartj/ehq013 CrossRefPubMed

58.

Coffey S, Williams MJ, Phillips LV, Jones GT (2015) Circulating microRNA profiling needs further refinement before clinical use in patients with aortic stenosis. J Am Heart Assoc 4(8):e002150. doi:10.1161/JAHA.115.002150 CrossRefPubMedPubMedCentral

59.

Fleissner F, Jazbutyte V, Fiedler J, Gupta SK, Yin X, Xu Q, Galuppo P, Kneitz S, Mayr M, Ertl G, Bauersachs J, Thum T (2010) Short communication: asymmetric dimethylarginine impairs angiogenic progenitor cell function in patients with coronary artery disease through a microRNA-21-dependent mechanism. Circ Res 107(1):138–143. doi:10.1161/CIRCRESAHA.110.216770 CrossRefPubMed

60.

Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu WT (2007) Altered microRNA expression in human heart disease. Physiol Genom 31(3):367–373.doi: 10.1152/physiolgenomics.00144.2007 CrossRef

61.

Sygitowicz G, Tomaniak M, Blaszczyk O, Koltowski L, Filipiak KJ, Sitkiewicz D (2015) Circulating microribonucleic acids miR-1, miR-21 and miR-208a in patients with symptomatic heart failure: preliminary results. Arch Cardiovasc Dis 108(12):634–642. doi:10.1016/j.acvd.2015.07.003 CrossRefPubMed

62.

Villar AV, Garcia R, Merino D, Llano M, Cobo M, Montalvo C, Martin-Duran R, Hurle MA, Nistal JF (2013) Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients. Int J Cardiol 167(6):2875–2881. doi:10.1016/j.ijcard.2012.07.021 CrossRefPubMed

63.

Liu X, Dong Y, Chen S, Zhang G, Zhang M, Gong Y, Li X (2015) Circulating microRNA-146a and microRNA-21 predict left ventricular remodeling after ST-elevation myocardial infarction. Cardiology 132(4):233–241. doi:10.1159/000437090 CrossRefPubMed

64.

Guo C, Deng Y, Liu J, Qian L (2015) Cardiomyocyte-specific role of miR-24 in promoting cell survival. J Cell Mol Med 19(1):103–112. doi:10.1111/jcmm.12393 CrossRefPubMed

65.

Wang K, Lin ZQ, Long B, Li JH, Zhou J, Li PF (2012) Cardiac hypertrophy is positively regulated by MicroRNA miR-23a. J Biol Chem 287(1):589–599. doi:10.1074/jbc.M111.266940 CrossRefPubMed

Title: MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children
Authors: Ma. C. Sánchez-Gómez
K. A. García-Mejía
M. Pérez-Díaz Conti
G. Díaz-Rosas
I. Palma-Lara
R. Sánchez-Urbina
M. Klünder-Klünder
J. A. Botello-Flores
N. A. Balderrábano- Saucedo
A. Contreras-Ramos
Publication date: 01-06-2017
Publisher: Springer US
Published in: Pediatric Cardiology / Issue 5/2017
Print ISSN: 0172-0643
Electronic ISSN: 1432-1971
DOI: https://doi.org/10.1007/s00246-017-1607-8

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

MicroRNAs Association in the Cardiac Hypertrophy Secondary to Complex Congenital Heart Disease in Children

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2017

Clinical Application of the QRS-T Angle for the Prediction of Ventricular Arrhythmias in Patients with the Fontan Palliation

Z-score of Mitral Annular Plane Systolic Excursion is a Useful Indicator of Evaluation of Left Ventricular Function in Patients with Acute-Phase Kawasaki Disease

Erratum to: Decreased Diastolic Ventricular Kinetic Energy in Young Patients with Fontan Circulation Demonstrated by Four-Dimensional Cardiac Magnetic Resonance Imaging

Distribution of Kawasaki Disease Coronary Artery Aneurysms and the Relationship to Coronary Artery Diameter

Relationship Between Fragmented QRS Complexes and Cardiac Status in Duchenne Muscular Dystrophy: Multimodal Validation Using Echocardiography, Magnetic Resonance Imaging, and Holter Monitoring

Red Flags for Maltese Adults with Congenital Heart Disease: Poorer Dental Care and Less Sports Participation Compared to Other European Patients—An APPROACH-IS Substudy

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page